Aldosterone and TGF-β1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells

American Journal of Physiology - Renal Physiology

Volumn 294, Issue 6, 2008, Pages

  Huang, Wei ^a   Xu, Chen ^a   Kahng, Kyoung W ^a   Noble, Nancy A ^a   Border, Wayne A ^a   Huang, Yufeng ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Fibrosis Research Laboratory   (United States)

Author keywords

Plasminogen activator inhibitor 1; Transforming growth factor

Indexed keywords

ALDOSTERONE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; KIDNEY CELL; KIDNEY FUNCTION; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION; GENETICS; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ALDOSTERONE; ANIMALS; CELLS, CULTURED; DRUG SYNERGISM; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; KIDNEY DISEASES; MESANGIAL CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, WISTAR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 48249139468     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00017.2008     Document Type: Article

References (56)

1. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306-3314, 2005.
2. Asai M, Monkawa T, Marumo T, Fukuda S, Tsuji M, Yoshino J, Kawachi H, Shimizu F, Hayashi M, Saruta T. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res 27: 971-978, 2004.
3. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47: 1039-1047, 1995.
4. Baricos WH, Reed JC, Cortez SL. Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. Exp Biol Med (Maywood) 228: 1018-1022, 2003.
5. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63: 1791-1800, 2003.
6. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 31: 181-188, 1998.
7. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
8. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85: 336-344, 2000.
9. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219-1227, 2000.
10. Bruzdzinski CJ, Riordan-Johnson M, Nordby EC, Suter SM, Gelehrter TD. Isolation and characterization of the rat plasminogen activator inhibitor-1 gene. J Biol Chem 265: 2078-2085, 1990.
11. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925-926, 2001.
12. Chun TY, Pratt JH. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol Cell Endocrinol 239: 55-61, 2005.
13. Derynck R, Jarrett JA, Chen EY, Goeddel DV. The murine transforming growth factor-beta precursor. J Biol Chem 261: 4377-4379, 1986.
14. Doulton TW. ACE inhibitor-angiotensin receptor blocker combinations: a clinician's perspective. Mini Rev Med Chem 6: 491-497, 2006.
15. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283: F209-F220, 2002.
16. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 94: 378-383, 2001.
17. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101: 594-597, 2000.
18. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 41: 31-36, 2003.
19. Fort P, Marty L, Piechaczyk M, Sabrouty SE, Dani C, Jeanteur PH, Blanchard JM. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 13: 1431-1442, 1985.
20. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66: 1493-1502, 2004.
21. Gullulu M, Akdag I, Kahvecioglu S, Filiz G, Savci V. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Ren Fail 28: 509-514, 2006.
22. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111-120, 2006.
23. Huang Y, Border WA, Lawrence DA, Noble NA. Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int 70: 515-522, 2006.
24. Huang Y, Border WA, Noble NA. Perspectives on blockade of TGF beta overexpression. Kidney Int 69: 1713-1714, 2006.
25. Huang Y, Noble N. An unexpected role of plasminogen activator inhibitor-type 1 (PAI-1) in renal fibrosis. Kidney Int 67: 2502-2503, 2005.
26. Huang Y, Noble NA. PAI-1 as a target in kidney disease. Curr Drug Targets 8: 1007-1015, 2007.
27. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113, 2006.
28. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 286: F1059-F1062, 2004.
29. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994.
30. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51: 664-671, 1997.
31. Kramer AB, van der Meulen EF, Hamming I, van Goor H, Navis G. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 71: 417-424, 2007.
32. Lai L, Chen J, Hao CM, Lin S, Gu Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem Biophys Res Commun 348: 70-75, 2006.
33. Laug WE, Weinblatt ME, Jones PA. Endothelial cells degrade extracellular matrix proteins produced in vitro. Thromb Haemost 54: 498-502, 1985.
34. Li S, Wu P, Zhong S, Guo Z, Lai W, Zhang Y, Liang X, Xiu J, Li J, Liu Y. Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone. Horm Res 55: 293-297, 2001.
35. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69: 1064-1072, 2006.
36. Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 163: 1261-1273, 2003.
37. Morgan T, Anderson A, Bertram D, MacInnis RJ. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 5: 64-71, 2004.
38. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, Kiyomoto H, Kohno M, Abe Y, Yoshizumi M, Nishiyama A. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46: 1039-1045, 2005.
39. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093, 2006.
40. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, Abe Y. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45: 710-716, 2005.
41. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 22: 1314-1322, 2007.
42. Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292: F131-F139, 2007.
43. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54: 1570-1580, 1998.
44. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
45. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
46. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21: 471-475, 2004.
47. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458, 1998.
48. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47: 1936-1939, 2004.
49. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68: 2829-2836, 2005.
50. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70: 536-542, 2006.
51. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42: 1462-1469, 1992.
52. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney Int 72: 1164-1165, 2007.
53. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 345: 1689-1697, 2001.
54. Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int 64: 844-856, 2003.
55. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA. Combining TGF-β inhibition and angiotensin II blockade results in enhanced anti-fibrotic effect. Kidney Int 66: 1774-1784, 2004.
56. Yuan J, Jia R, Bao Y. Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol 40: 180-188, 2007.